Cargando…
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
Autor principal: | Kwok, Seung-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164720/ https://www.ncbi.nlm.nih.gov/pubmed/25228832 http://dx.doi.org/10.3904/kjim.2014.29.5.577 |
Ejemplares similares
-
Undetectable mannose binding lectin is associated with HRCT proven bronchiectasis in rheumatoid arthritis (RA)
por: Makin, Krista, et al.
Publicado: (2019) -
Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012) -
Mortality in Rheumatoid Arthritis (RA): factors associated with recording RA on death certificates
por: Molina, Emily, et al.
Publicado: (2015) -
Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia
por: Alzahrani, Zeyad, et al.
Publicado: (2022) -
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)